Innovation in Immunoassay Development: Use of High Throughput Screening (HTS) in the process development for the IVD Industry.

Innovation in Immunoassay Development 

Use of High Throughput Screening (HTS) in the process development for the IVD Industry

In the initial stages of the development of a new immunoassay, the selection of the right biomaterial as well as the definition of the formulation needs to be done in an efficient and timely way to reduce the risk in the later stages of the project where significant commitments are made and delays in the launch of the product could imply extra costs. 


Join us in the OEM series to hear how using High Throughput Screening has allowed us to evaluate more experimental conditions in an efficient way to reduce development time and de-risk in the initial stages of an immunoassay development project.

More information


Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy. You can also contact us at DPO-biokit@werfen.com.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.